Literature DB >> 10525561

Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis.

J Ashitani1, H Mukae, H Taniguchi, T Ihi, J Kadota, S Kohno, S Matsukura.   

Abstract

BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is known as a potent neutrophil chemotactic glycoprotein in vitro but its contribution to chemotactic activity in neutrophil mediated lung diseases is not yet known. The aims of this study were to determine whether G-CSF is present in high concentrations in bronchoalveolar lavage (BAL) fluid of patients with idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis), a neutrophil mediated lung disease, and to what extent G-CSF in BAL fluid contributes to neutrophil accumulation in the lung of patients with IPF.
METHODS: G-CSF concentrations in BAL fluid samples from 16 healthy volunteers, 24 patients with IPF, and 73 patients with non-IPF lung disease were measured by enzyme linked immunosorbent assay. The relationship between G-CSF concentrations and neutrophil count in BAL fluid was also examined. Neutrophil chemotactic activity (NCA) was measured in BAL fluid in healthy volunteers and patients with IPF. The contribution of G-CSF to overall NCA in lungs with IPF was assessed by repeating the measurement of NCA after a complete neutralisation of G-CSF bioactivity by anti-human G-CSF antiserum.
RESULTS: Detectable levels of G-CSF were found in BAL fluid of 83% of patients with IPF while the levels in all healthy volunteers were below the detection limit. In patients with IPF a significant correlation was observed between the BAL fluid neutrophil count and the concentration of G-CSF in the BAL fluid. The neutrophil count also correlated significantly with percentage forced vital capacity. In BAL fluid samples from patients with IPF the mean NCA value was reduced by 35% after neutralisation with an anti-human G-CSF antiserum.
CONCLUSIONS: G-CSF may be involved in enhancing neutrophil accumulation in the lungs of patients with IPF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525561      PMCID: PMC1745399          DOI: 10.1136/thx.54.11.1015

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

1.  Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis.

Authors:  A U Wells; D M Hansell; P L Haslam; M B Rubens; J Cailes; C M Black; R M du Bois
Journal:  Am J Respir Crit Care Med       Date:  1998-05       Impact factor: 21.405

2.  Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay.

Authors:  K Watari; S Asano; N Shirafuji; H Kodo; K Ozawa; F Takaku; S Kamachi
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

3.  Chemotactic activity of recombinant human granulocyte colony-stimulating factor.

Authors:  J M Wang; Z G Chen; S Colella; M A Bonilla; K Welte; C Bordignon; A Mantovani
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

4.  Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance.

Authors:  A U Wells; D M Hansell; M B Rubens; P Cullinan; P L Haslam; C M Black; R M Du Bois
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

5.  Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo.

Authors:  K L Yong; D C Linch
Journal:  Eur J Haematol       Date:  1992-11       Impact factor: 2.997

6.  Interleukin-8 expression in bronchoalveolar lavage cells in the evaluation of alveolitis in idiopathic pulmonary fibrosis.

Authors:  A Xaubet; C Agustí; P Luburich; J A Barberá; M Carrión; M C Ayuso; J Roca; R Rodriguez-Roisin
Journal:  Respir Med       Date:  1998-02       Impact factor: 3.415

7.  Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.

Authors:  K Oishi; F Sonoda; S Kobayashi; A Iwagaki; T Nagatake; K Matsushima; K Matsumoto
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

8.  Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis.

Authors:  T Ozaki; H Hayashi; K Tani; F Ogushi; S Yasuoka; T Ogura
Journal:  Am Rev Respir Dis       Date:  1992-01

9.  Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality.

Authors:  E J Miller; A B Cohen; S Nagao; D Griffith; R J Maunder; T R Martin; J P Weiner-Kronish; M Sticherling; E Christophers; M A Matthay
Journal:  Am Rev Respir Dis       Date:  1992-08

10.  Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.

Authors:  B D Car; F Meloni; M Luisetti; G Semenzato; G Gialdroni-Grassi; A Walz
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

View more
  10 in total

1.  Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease.

Authors:  Evelyn Tsantikos; Maverick Lau; Cassandra Mn Castelino; Mhairi J Maxwell; Samantha L Passey; Michelle J Hansen; Narelle E McGregor; Natalie A Sims; Daniel P Steinfort; Louis B Irving; Gary P Anderson; Margaret L Hibbs
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

2.  B7H3 expression and significance in idiopathic pulmonary fibrosis.

Authors:  Chuling Fang; Andrew E Rinke; Jing Wang; Kevin R Flaherty; Sem H Phan; Tianju Liu
Journal:  J Pathol       Date:  2021-12-22       Impact factor: 7.996

Review 3.  Our evolving view of neutrophils in defining the pathology of chronic lung disease.

Authors:  Kyle T Mincham; Nicoletta Bruno; Aran Singanayagam; Robert J Snelgrove
Journal:  Immunology       Date:  2021-10-04       Impact factor: 7.215

4.  Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.

Authors:  H Mukae; H Iiboshi; M Nakazato; T Hiratsuka; M Tokojima; K Abe; J Ashitani; J Kadota; S Matsukura; S Kohno
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

5.  Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosis.

Authors:  Nadine Binai; Steven O'Reilly; Bridget Griffiths; Jacob M van Laar; Thomas Hügle
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

6.  Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis.

Authors:  Julianne N P Smith; Matthew D Witkin; Alvin P Jogasuria; Kelsey F Christo; Thomas M Raffay; Sanford D Markowitz; Amar B Desai
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

7.  The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease.

Authors:  Kristel S Knudsen; Sverre Lehmann; Rune Nielsen; Solveig Tangedal; Ingvild Haaland; Pieter S Hiemstra; Tomas M Eagan
Journal:  PLoS One       Date:  2022-01-06       Impact factor: 3.240

Review 8.  Implications of the Immune Landscape in COPD and Lung Cancer: Smoking Versus Other Causes.

Authors:  Elisabeth Taucher; Iurii Mykoliuk; Joerg Lindenmann; Freyja-Maria Smolle-Juettner
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

9.  Granulocyte colony-stimulating factor in bronchoalveolar lavage fluid is a potential biomarker for prognostic prediction of idiopathic pulmonary fibrosis.

Authors:  Jong-Uk Lee; Jae Sung Choi; Min Kyung Kim; Sun A Min; Jong-Sook Park; Choon-Sik Park
Journal:  Korean J Intern Med       Date:  2022-06-22       Impact factor: 3.165

10.  Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.

Authors:  Elena Atanasova; Dragana Milosevic; Svetlana Bornschlegl; Karen P Krucker; Eapen K Jacob; Eva M Carmona Porquera; Dagny K Anderson; Ashley M Egan; Andrew H Limper; Allan B Dietz
Journal:  Stem Cell Res Ther       Date:  2022-01-31       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.